DK0735896T3 - Parathyroideahormonformulering - Google Patents
ParathyroideahormonformuleringInfo
- Publication number
- DK0735896T3 DK0735896T3 DK95903732T DK95903732T DK0735896T3 DK 0735896 T3 DK0735896 T3 DK 0735896T3 DK 95903732 T DK95903732 T DK 95903732T DK 95903732 T DK95903732 T DK 95903732T DK 0735896 T3 DK0735896 T3 DK 0735896T3
- Authority
- DK
- Denmark
- Prior art keywords
- parathyroid hormone
- hormone formulation
- excipient
- buffering agent
- formulation
- Prior art date
Links
- 239000000199 parathyroid hormone Substances 0.000 title abstract 3
- 108090000445 Parathyroid hormone Proteins 0.000 title abstract 2
- 102000003982 Parathyroid hormone Human genes 0.000 title abstract 2
- 229960001319 parathyroid hormone Drugs 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000006172 buffering agent Substances 0.000 abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 2
- 238000002360 preparation method Methods 0.000 abstract 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 abstract 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
- 101001135770 Homo sapiens Parathyroid hormone Proteins 0.000 abstract 1
- 101001135995 Homo sapiens Probable peptidyl-tRNA hydrolase Proteins 0.000 abstract 1
- 229930195725 Mannitol Natural products 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 102000058004 human PTH Human genes 0.000 abstract 1
- 239000000594 mannitol Substances 0.000 abstract 1
- 235000010355 mannitol Nutrition 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/172,206 US5496801A (en) | 1993-12-23 | 1993-12-23 | Parathyroid hormone formulation |
| PCT/CA1994/000693 WO1995017207A1 (en) | 1993-12-23 | 1994-12-16 | Parathyroid hormone formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0735896T3 true DK0735896T3 (da) | 2008-02-04 |
Family
ID=22626763
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK95903732T DK0735896T3 (da) | 1993-12-23 | 1994-12-16 | Parathyroideahormonformulering |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US5496801A (da) |
| EP (2) | EP1880732A1 (da) |
| JP (1) | JP3065662B2 (da) |
| KR (1) | KR100398461B1 (da) |
| CN (1) | CN1116897C (da) |
| AT (1) | ATE374621T1 (da) |
| AU (1) | AU681737B2 (da) |
| BR (1) | BR9408398A (da) |
| CA (1) | CA2179207C (da) |
| CZ (1) | CZ184296A3 (da) |
| DE (1) | DE69435033T2 (da) |
| DK (1) | DK0735896T3 (da) |
| ES (1) | ES2293637T3 (da) |
| FI (1) | FI120291B (da) |
| HK (1) | HK1010336A1 (da) |
| HU (1) | HUT74381A (da) |
| LV (1) | LV11731B (da) |
| NO (1) | NO324905B1 (da) |
| NZ (1) | NZ277463A (da) |
| PL (1) | PL315158A1 (da) |
| PT (1) | PT735896E (da) |
| SK (1) | SK82896A3 (da) |
| WO (1) | WO1995017207A1 (da) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5563122A (en) * | 1991-12-09 | 1996-10-08 | Asahi Kasei Kogyo Kabushiki Kaisha | Stabilized parathyroid hormone composition |
| US6509316B2 (en) * | 1995-03-07 | 2003-01-21 | George Washington University | Pharmaceutical compositions, methods, and kits for treatment and diagnosis of lung cancer |
| SE9702401D0 (sv) * | 1997-06-19 | 1997-06-19 | Astra Ab | Pharmaceutical use |
| WO1999004808A1 (fr) * | 1997-07-22 | 1999-02-04 | Chugai Seiyaku Kabushiki Kaisha | Medicaments dentaires contenant de la pth |
| MY120063A (en) * | 1997-12-09 | 2005-08-30 | Lilly Co Eli | Stabilized teriparatide solutions |
| US6770623B1 (en) * | 1997-12-09 | 2004-08-03 | Eli Lilly And Company | Stabilized teriparatide solutions |
| KR20010033268A (ko) * | 1997-12-18 | 2001-04-25 | 피터 지. 스트링거 | 결정형 테리파라타이드 |
| SE9801495D0 (sv) * | 1998-04-28 | 1998-04-28 | Astra Ab | Protein formulationa |
| US6495662B1 (en) * | 1998-10-22 | 2002-12-17 | The General Hospital Corporation | Bioactive peptides and peptide derivatives of parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHrP) |
| AU4217299A (en) * | 1998-11-30 | 2000-06-19 | General Hospital Corporation, The | Pth1r and pth3r receptors, methods and uses thereof |
| US7820393B2 (en) * | 1999-01-14 | 2010-10-26 | Scantibodies Laboratory, Inc. | Methods, kits and antibodies for detecting parathyroid hormone |
| US6689566B1 (en) | 1999-01-14 | 2004-02-10 | Scantibodies Laboratory, Inc. | Methods, kits, and antibodies for detecting parathyroid hormone |
| WO2004028444A2 (en) * | 1999-06-02 | 2004-04-08 | Scantibodies Laboratory, Inc. | Parathyroid hormone antagonists and uses thereof |
| US20080108086A1 (en) * | 1999-06-02 | 2008-05-08 | Cantor Thomas L | Parathyroid hormone antagonists and uses thereof |
| CZ200260A3 (cs) * | 1999-07-12 | 2002-04-17 | Grandis Biotech Gmbh | Formulace růstového hormonu |
| AU7734800A (en) * | 1999-09-29 | 2001-04-30 | General Hospital Corporation, The | Polypeptide derivatives of parathyroid hormone (pth) |
| CA2399505C (en) | 2000-02-04 | 2012-01-03 | Unigene Laboratories, Inc. | Nasal calcitonin formulations |
| US20020061838A1 (en) * | 2000-05-17 | 2002-05-23 | Barton Holmquist | Peptide pharmaceutical formulations |
| US6905886B2 (en) * | 2000-08-11 | 2005-06-14 | Quest Diagnostics Investments Incorporated | Preservative solutions |
| US6387711B1 (en) * | 2000-08-11 | 2002-05-14 | Quest Diagnostics Investments Incorporated | Liquid intact parathyroid hormone (PTH) standards |
| ATE314822T1 (de) * | 2000-10-10 | 2006-02-15 | Microchips Inc | Mikrochip-reservoir-vorrichtungen mit drahtloser übertragung von energie und daten |
| KR100491737B1 (ko) * | 2001-07-20 | 2005-05-27 | 주식회사 한국아이템개발 | 공기 정화 기능의 모기 퇴치기 |
| JP4837888B2 (ja) | 2001-07-23 | 2011-12-14 | ザ ジェネラル ホスピタル コーポレイション | コンホメーションが拘束された副甲状腺ホルモン（ｐｔｈ）類似体 |
| US7497855B2 (en) * | 2002-09-04 | 2009-03-03 | Microchips, Inc. | Method and device for the controlled delivery of parathyroid hormone |
| US20040067526A1 (en) * | 2002-10-03 | 2004-04-08 | Cantor Thomas L. | Methods for diagnosing and guiding treatment of bone turnover disease |
| EP1610813A4 (en) * | 2003-03-19 | 2009-07-01 | Gen Hospital Corp | PARATHYROIDAL HORMONES CONFORMALLY CONFORMALLY CONSTRAINED WITH PROPELLER STABILIZERS $ G (A) |
| JP5456234B2 (ja) | 2003-06-30 | 2014-03-26 | アルザ・コーポレーシヨン | 非揮発性の対イオンを含有する被覆された微小突起のための製剤 |
| KR100540659B1 (ko) * | 2003-07-02 | 2006-01-10 | 삼성전자주식회사 | 이미지 확대 인쇄 방법과 장치 및 컴퓨터 프로그램을저장하는 컴퓨터로 읽을 수 있는 기록 매체 |
| WO2005014034A1 (en) * | 2003-07-14 | 2005-02-17 | Nps Allelix Corp. | Stabilized formulation of parathyroid hormone |
| WO2005009358A2 (en) | 2003-07-17 | 2005-02-03 | The General Hospital Corporation | Conformationally constrained parathyroid hormone (pth) analogs |
| US7459276B2 (en) * | 2003-09-29 | 2008-12-02 | Scantibodies Laboratory, Inc. | Methods and controls for monitoring assay quality and accuracy in parathyroid hormone measurement |
| US20050119183A1 (en) * | 2003-11-12 | 2005-06-02 | Nps Allelix Corp. | Method for treating bone loss using parathyroid hormone |
| US20050106209A1 (en) * | 2003-11-13 | 2005-05-19 | Mahmoud Ameri | Composition and apparatus for transdermal delivery |
| CN100406059C (zh) * | 2004-04-30 | 2008-07-30 | 陈新梅 | 甲状旁腺激素的新用途 |
| BRPI0509788A (pt) * | 2004-05-13 | 2007-10-23 | Alza Corp | aparato e método para liberação transdérmica de agentes de hormÈnio paratireóides |
| US7541140B2 (en) * | 2004-06-03 | 2009-06-02 | Scantibodies Laboratory, Inc. | Assessing risk for kidney stones using parathyroid hormone agonist and antagonist |
| US20080076975A1 (en) * | 2005-01-25 | 2008-03-27 | Microchips, Inc. | Method and implantable device with reservoir array for pre-clinical in vivo testing |
| AU2006208131A1 (en) * | 2005-01-25 | 2006-08-03 | Microchips, Inc. | Control of drug release by transient modification of local microenvironments |
| KR100700869B1 (ko) * | 2005-06-03 | 2007-03-29 | 재단법인 목암생명공학연구소 | Ｐｔｈ, 완충제 및 안정제를 포함하는 안정한 ｐｔｈ조성물 |
| AU2006315132A1 (en) * | 2005-11-10 | 2007-05-24 | Board Of Control Of Michigan Technological University | Black bear parathyroid hormone and methods of using black bear parathyroid hormone |
| EP2054077A4 (en) * | 2006-08-04 | 2010-10-13 | Gen Hospital Corp | POLYPEPTIDE DERIVATIVES OF PARATHYROID HORMONE (PTH) |
| EP1961765A1 (en) * | 2006-12-08 | 2008-08-27 | Zealand Pharma A/S | Truncated PTH peptides with a cyclic conformation |
| AU2008282805B2 (en) * | 2007-08-01 | 2014-05-01 | Chugai Pharmaceutical Co., Ltd. | Screening methods using G-protein coupled receptors and related compositions |
| US8298789B2 (en) * | 2007-08-09 | 2012-10-30 | Usv Limited | Orthogonal process for purification of recombinant human parathyroid hormone (rhPTH) (1-34) |
| JP2009091363A (ja) * | 2008-11-21 | 2009-04-30 | Asahi Kasei Pharma Kk | Ｐｔｈの安定化水溶液注射剤 |
| EP2509996A1 (en) | 2009-12-07 | 2012-10-17 | Michigan Technological University | Black bear parathyroid hormone and methods of using black bear parathyroid hormone |
| BR112012028949B1 (pt) | 2010-05-13 | 2020-11-17 | Chugai Seiyaku Kabushiki Kaisha | polipeptídeo análogo do hormônio paratireoideo, seu uso e método de produção, bem como ácido nucleico, vetor de expressão, célula e composição farmacêutica |
| AU2012225268B2 (en) * | 2011-03-10 | 2016-10-20 | Xeris Pharmaceuticals, Inc. | Stable formulations for parenteral injection of peptide drugs |
| CN108195965B (zh) * | 2011-06-07 | 2021-02-23 | 旭化成制药株式会社 | 含pth肽冷冻干燥制剂的检査方法及包含该含pth肽冷冻干燥制剂的医药品的制造方法 |
| CA2904077A1 (en) | 2013-03-15 | 2014-09-25 | Psivida Us, Inc. | Bioerodible silicon-based compositions for delivery of therapeutic agents |
| CN103301058A (zh) * | 2013-06-17 | 2013-09-18 | 深圳翰宇药业股份有限公司 | 一种特立帕肽注射用组合物及其制备方法和制剂 |
| JP7399382B2 (ja) * | 2018-07-30 | 2023-12-18 | 武田薬品工業株式会社 | 組換えヒト副甲状腺ホルモンの安定性を向上させるための製剤 |
| CN110917150A (zh) * | 2019-12-31 | 2020-03-27 | 北京博康健基因科技有限公司 | 一种pth冻干制剂及其制备方法 |
| CN115279396A (zh) * | 2020-03-30 | 2022-11-01 | 四川泸州步长生物制药有限公司 | 人类甲状旁腺激素(pth)的制剂及用于生产其的方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3768177A (en) * | 1972-08-02 | 1973-10-30 | R Thomas | Educational device |
| US4105602A (en) * | 1975-02-10 | 1978-08-08 | Armour Pharmaceutical Company | Synthesis of peptides with parathyroid hormone activity |
| US4016314A (en) * | 1975-06-26 | 1977-04-05 | Hallco Inc. | Embroidered fruit bowl wall hanging and kit for making same |
| US4199060A (en) * | 1978-07-20 | 1980-04-22 | Howard Hardware Products, Inc. | Lock installation kit |
| US4424278A (en) * | 1981-11-16 | 1984-01-03 | Research Corporation | Cancer detection procedure using an acyl carrier protein |
| JPS61267528A (ja) * | 1984-11-26 | 1986-11-27 | Yamanouchi Pharmaceut Co Ltd | 吸収促進剤を含有するカルシトニン経鼻剤 |
| US4812311A (en) * | 1984-12-21 | 1989-03-14 | The Procter & Gamble Company | Kit for use in the treatment of osteoporosis |
| IL78342A (en) * | 1985-04-04 | 1991-06-10 | Gen Hospital Corp | Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof |
| JPS6360940A (ja) * | 1986-09-01 | 1988-03-17 | Toyo Jozo Co Ltd | 白内障の予防または治療剤 |
| US4833125A (en) * | 1986-12-05 | 1989-05-23 | The General Hospital Corporation | Method of increasing bone mass |
| US5059587A (en) * | 1987-08-03 | 1991-10-22 | Toyo Jozo Company, Ltd. | Physiologically active peptide composition for nasal administration |
| US5011678A (en) * | 1989-02-01 | 1991-04-30 | California Biotechnology Inc. | Composition and method for administration of pharmaceutically active substances |
| DE3935738A1 (de) * | 1989-10-27 | 1991-05-08 | Forssmann Wolf Georg | Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff |
| GB9020544D0 (en) * | 1990-09-20 | 1990-10-31 | Sandoz Ltd | Improvements in or relating to organic compounds |
| JP3090353B2 (ja) * | 1991-09-17 | 2000-09-18 | 旭化成工業株式会社 | パラチロイドホルモン類含有経鼻投与用乳剤 |
| US5563122A (en) * | 1991-12-09 | 1996-10-08 | Asahi Kasei Kogyo Kabushiki Kaisha | Stabilized parathyroid hormone composition |
| SK74594A3 (en) * | 1991-12-17 | 1995-01-12 | Procter & Gamble Pharma | Treatment for treating of osteoporosis |
| IT1255723B (it) * | 1992-10-09 | 1995-11-13 | Uso di paratormone,suoi frammenti biologicamente attivi e peptidi correlati, per la preparazione di composizioni farmaceutiche utili nella prevenzione e terapia dell'aborto e del parto pretermine ed in generale per il trattamento della gestazione |
-
1993
- 1993-12-23 US US08/172,206 patent/US5496801A/en not_active Expired - Lifetime
-
1994
- 1994-12-16 CA CA002179207A patent/CA2179207C/en not_active Expired - Lifetime
- 1994-12-16 AU AU12698/95A patent/AU681737B2/en not_active Expired
- 1994-12-16 WO PCT/CA1994/000693 patent/WO1995017207A1/en active IP Right Grant
- 1994-12-16 EP EP07019169A patent/EP1880732A1/en not_active Withdrawn
- 1994-12-16 KR KR1019960703288A patent/KR100398461B1/ko not_active IP Right Cessation
- 1994-12-16 CZ CZ961842A patent/CZ184296A3/cs unknown
- 1994-12-16 HU HU9601721A patent/HUT74381A/hu unknown
- 1994-12-16 AT AT95903732T patent/ATE374621T1/de active
- 1994-12-16 JP JP7517064A patent/JP3065662B2/ja not_active Expired - Lifetime
- 1994-12-16 PT PT95903732T patent/PT735896E/pt unknown
- 1994-12-16 CN CN94194608A patent/CN1116897C/zh not_active Expired - Lifetime
- 1994-12-16 BR BR9408398A patent/BR9408398A/pt not_active Application Discontinuation
- 1994-12-16 EP EP95903732A patent/EP0735896B1/en not_active Expired - Lifetime
- 1994-12-16 ES ES95903732T patent/ES2293637T3/es not_active Expired - Lifetime
- 1994-12-16 SK SK828-96A patent/SK82896A3/sk unknown
- 1994-12-16 DK DK95903732T patent/DK0735896T3/da active
- 1994-12-16 NZ NZ277463A patent/NZ277463A/en not_active IP Right Cessation
- 1994-12-16 PL PL94315158A patent/PL315158A1/xx unknown
- 1994-12-16 DE DE69435033T patent/DE69435033T2/de not_active Expired - Lifetime
-
1996
- 1996-06-20 NO NO19962634A patent/NO324905B1/no not_active IP Right Cessation
- 1996-06-20 FI FI962593A patent/FI120291B/fi not_active IP Right Cessation
- 1996-07-19 LV LVP-96-283A patent/LV11731B/en unknown
-
1998
- 1998-10-08 HK HK98111127A patent/HK1010336A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| US5496801A (en) | 1996-03-05 |
| EP1880732A1 (en) | 2008-01-23 |
| HUT74381A (en) | 1996-12-30 |
| AU681737B2 (en) | 1997-09-04 |
| BR9408398A (pt) | 1997-08-12 |
| HU9601721D0 (en) | 1996-08-28 |
| NO962634D0 (no) | 1996-06-20 |
| NO962634L (no) | 1996-06-20 |
| DE69435033D1 (de) | 2007-11-15 |
| EP0735896A1 (en) | 1996-10-09 |
| ATE374621T1 (de) | 2007-10-15 |
| FI962593A0 (fi) | 1996-06-20 |
| FI962593A (fi) | 1996-08-19 |
| PT735896E (pt) | 2007-12-07 |
| LV11731A (lv) | 1997-04-20 |
| CA2179207C (en) | 2000-11-14 |
| EP0735896B1 (en) | 2007-10-03 |
| NO324905B1 (no) | 2007-12-27 |
| NZ277463A (en) | 1997-03-24 |
| CN1116897C (zh) | 2003-08-06 |
| PL315158A1 (en) | 1996-10-14 |
| LV11731B (en) | 1997-08-20 |
| ES2293637T3 (es) | 2008-03-16 |
| WO1995017207A1 (en) | 1995-06-29 |
| HK1010336A1 (en) | 1999-06-17 |
| AU1269895A (en) | 1995-07-10 |
| KR100398461B1 (ko) | 2004-03-20 |
| CA2179207A1 (en) | 1995-06-29 |
| FI120291B (fi) | 2009-09-15 |
| DE69435033T2 (de) | 2008-05-29 |
| JPH09506869A (ja) | 1997-07-08 |
| SK82896A3 (en) | 1997-01-08 |
| JP3065662B2 (ja) | 2000-07-17 |
| CZ184296A3 (en) | 1997-01-15 |
| CN1142772A (zh) | 1997-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0735896T3 (da) | Parathyroideahormonformulering | |
| ES2055845T3 (es) | Composicion farmaceutica para el tratamiento de la osteoporosis. | |
| UA72884C2 (uk) | Стабілізовані розчини паратирину | |
| BR9402902A (pt) | Hormônio paratiróideo e raloxifeno, compostos e formulação farmacêutica. | |
| IE882671L (en) | Stabilised human protein formulation | |
| CA2027592A1 (en) | Solid pharmaceutical preparations of active form of vitamin d_ of improved stability | |
| AU5561686A (en) | Method of increasing bone mass | |
| NO891007L (no) | Farmasoeytiske polypeptidholdige preparater. | |
| NO950123D0 (no) | Paratyreoidea hormonforbindelser, fremgangsmåte for deres fremstilling og farmasöytiske preparater inneholdende disse | |
| NZ230280A (en) | Pharmaceutical formulation containing an insulin derivative modified with a base, with an isoelectric point between 5.8 - 8.5, and with a zinc ion content of from 2mug - 200mug of zinc/iu | |
| SE8504945L (sv) | Farmaceutiska kompositioner innehallande antracyklinglykosider | |
| DK0588539T3 (da) | Stabiliserede farmaceutiske præparater indeholdende derivater af vitamin D2 og D3 | |
| EP0543521A3 (en) | High dosage topical forms of collagenase | |
| DK0582239T3 (da) | Farmaceutisk og/eller kosmetisk formulering | |
| IL140140A0 (en) | Thyroid hormone analogues and methods for their preparation | |
| GB8918879D0 (en) | Pharmaceutical compositions | |
| HUT47436A (en) | Process for stabilizing pharmaceutically active proteines in pharmaceutical compositions | |
| IL92061A0 (en) | Pharmaceutical compositions containing biologically active peptides and certain anions | |
| AU4685389A (en) | Pharmaceutical compositions and use thereof in the treatment of psoriasis | |
| AU3004192A (en) | Stabilized pharmaceutical composition of non-glycosylated recombinant human IL2 in reduced form and its preparation process | |
| DE69430996T2 (de) | Verfahren zur trockenmischungkompression von arzneimitteln | |
| EP0265338A3 (en) | Stable therapeutical compositions based on hydrophobic vegetable oil, and process for preparing them | |
| IT1247695B (it) | Composizioni farmaceutiche a base di calcitonina somministrabili per via nasale in terapia umana |